Artera

Artera is a commercial-stage diagnostics company using multimodal AI to personalize cancer therapy, starting with prostate cancer. Its FDA-authorized ArteraAI Prostate Test helps identify patients with biochemical recurrence who may benefit from intensified salvage therapy, guiding treatment decisions for clinicians. The company has established significant clinical validation, guideline inclusion, and commercial traction with over 400 institutions. Artera is expanding its platform into new cancer types, including breast cancer, positioning itself at the intersection of AI, digital pathology, and precision oncology.

Multimodal Artificial Intelligence (MMAI) platform that analyzes digitized histopathology images and clinical data to generate prognostic and predictive biomarkers for cancer therapy personalization.

Artera competes in the emerging field of AI-powered clinical diagnostics for oncology. Direct competitors include other companies developing AI-based prognostic tools from pathology images (e.g., Paige, PathAI). It also faces competition from traditional genomic-based tests in prostate cancer (e.g., Decipher, Oncotype DX GPS). Artera's first-mover FDA authorization and NCCN guideline recommendation for a predictive AI test in prostate cancer provide a distinct early advantage.